Hematology cancers include blood and lymphatic system disorders.

The Hematology Cancer Disease Site Group (Hematology DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. Reports produced by this group are available below.

• Treatment with Fludarabine for Patients with Follicular and other Low Grade Non-Hodgkin's Lymphoma and Waldenstrom's Macroglobulinemia
  6-2 PG: November 2001
  
  • Summary
  • Summary & Full Report
• The Role of Bisphosphonates in the Management of Skeletal Complications for Patients with Multiple Myeloma
  6-4 EBS: March 2007 Update
  
  • Practice Guideline
  • Evidence-Based Series
• Optimal Therapy for Patients Diagnosed with Multiple Myeloma and the Role of High-Dose Chemotherapy and Stem Cell Support
  6-6 PG: October 2003 Update
  
  • Summary
  • Summary & Full Report
• The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive Histology Non-Hodgkin's Lymphoma
  6-7 PG: July 2003
  
  • Summary
  • Summary & Full Report
• Rituximab in Lymphoma and Chronic Lymphocytic Leukemia
  6-8 EBS Version 2.2005: December 2006 Update
  
  • Practice Guideline
  • Evidence-Based Series
• The Management of Malignant Thrombocytosis in Philadelphia Chromosome-Negative Myeloproliferative Disease
  6-9 EBS: January 2008
  
  • Practice Guideline
  • Evidence-Based Series
• Treatment of Anemia with Erythropoietic Agents in Patients with Cancer – Adaption/Adoption of ASH-ASCO Guidelines
  6-11: January 2010
  
  • Summary
  • Summary & Full Report
• Treatment for Anemia with Erythropoietic Agents in Patients with non-Myeloid Hematological Malignancies
  EBS #6-12 has been replaced by EBS #6-11 Treatment of Anemia with Erythropoietic Agents in Patients with Cancer – Adaption/Adoption of ASH-ASCO Guidelines
• Treatment of Acute Myeloid Leukemia in Older Patients
  6-14 EBS: December 2008
  
  • Practice Guideline
  • Evidence-Based Series
• Treatment of Chronic Myeloid Leukemia with Imatinib
  6-15 PG: July 2004
  
  • Summary
  • Summary & Full Report
• Alemtuzumab in Chronic Lymphocytic Leukemia
  6-16 EBS: June 2006
  
  • Practice Guideline
  • Evidence-Based Series
• Ibritumomab Tiuxetan in Lymphoma
  6-17 EBS: July 2006
  
  • Practice Guideline
  • Evidence-Based Series
• Bortezomib in Multiple Myeloma and Lymphoma
  6-18 EBS: April 2006
  
  • Practice Guideline
  • Evidence-Based Series
• Iodine-131 Tositumomab in Lymphoma
  6-19 EBS: January 2007
  
  • Practice Guideline
  • Evidence-Based Series
• Thalidomide in Multiple Myeloma: Guideline Recommendations
  6-21: January 2010
  
  • Summary
  • Summary & Full Report

The following EBS reports are in development and only their titles are available at this time:
Positron Emission Tomography (PET) in Lymphoma (6-20 EBS)


Fludarabine in Intermediate- and High-Risk Chronic Lymphocytic Leukemia
6-1 PG: This guideline needs to be updated but is not on the current agenda for the Hematology DSG. The original guideline is available upon request at ccopgi@mcmaster.ca [2006 17 Jul].

Drug Therapy for Chronic Myeloid Leukemia
6-3 PG: This guideline is a historical document and is available upon request at ccopgi@mcmaster.ca . Current treatment recommendations for chronic myeloid leukemia are reflected in guideline 6-15 Treatment of Chronic Myeloid Leukemia with Imatinib.





Contact:
Program in Evidence-Based Care (PEBC)
McMaster University, Henderson Site
60 (G) Wing, 2nd Floor
711 Concession Street
Hamilton, Ontario, Canada
L8V 1C3

Phone: 905.527.4322 ext. 42822
Fax: 905.526.6775
Email: ccopgi@mcmaster.ca